Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In the case of the GLP-1 drugs, the weight loss caused by the initial drop in appetite is undercut by an apparent exponential increase in caloric intake as our body ratchets up our hunger again
Peter covers the latest findings in this rapidly evolving landscape, including new insights into their long-term efficacy, side effects, and what happens when the drug is discontinued
Sleep disruption changes the microbiome, as is shown in experiments where alterations in gut bacterial profiles were found in mice with circadian rhythm mutations or rats with chronic sleep deprivation (Chandra et al., 2023)
Case reports and pharmacovigilance data suggest psychiatric adverse events can occur with incretin-based therapies
Researchers are currently trying to pin down the biomarker signatures that indicate if a person will respond well to GLP-1 RAs
